Status:
COMPLETED
Observational Study on Safety of Self-titration of Once Daily Levemir®
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
This study is conducted in Europe. The main objective of the study is to assess the safety of self-titration in type 2 diabetic patients on antidiabetic tablets who are receiving insulin for the first...
Eligibility Criteria
Inclusion
- After the participating physician/nurse's decision has been made to initiate once daily Levemir® therapy (within the license of the product), any patient with type 2 diabetes of 18 years or older who is currently treated with diet, exercise and one or more OADs can be offered to participate
Exclusion
- Patients unable to give written informed consent
- Current treatment with insulin
- Patient deemed unable or unwilling to self-titrate
- Known or suspected allergy to study product or related products
- Pregnancy or breastfeeding or intention of becoming pregnant within the next 6 months
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
882 Patients enrolled
Trial Details
Trial ID
NCT00740519
Start Date
September 1 2008
End Date
March 1 2011
Last Update
February 3 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Crawley, United Kingdom, RH11 9RT